IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use...
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use...
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For...
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and...
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved...
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide...
Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular...
The addition of UCB’s Bimzelx in the EU and pending US approval adds to the growing momentum of the class,...
[Exton, PA., January 18, 2024]—Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis...
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix...
Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for...
According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy....
Ophthalmologists’ reservations about using Syfovre in Geographic Atrophy are more limited to “new start” patients, according to Spherix Global Insights. ...